

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, February 15, 2023, 9 a.m. to 1:45 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Alex Park, Committee Chair
9:05 a.m.	P&T Committee process overview	Donna Sullivan, HCA
9:45 a.m.	Washington PDL archived and removed classes	Donna Sullivan, HCA
10 a.m.	CGRP- report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Sara Kennedy, DERP
11 a.m.	Pharmacy & Therapeutics Committee Adjourns Break (10 min)	Alex Park, Committee Chair All
11:10 a.m.	Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Alex Park, Committee Chair
11:10 a.m.	Antibiotics <ul style="list-style-type: none"> • Aminoglycosides - Inhaled • Monobactams – Inhaled <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:20 a.m.	Respiratory Agents <ul style="list-style-type: none"> • Cystic Fibrosis Agents • Cystic Fibrosis Agents - CFTR Potentiators <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:30 a.m.	Anticoagulants <ul style="list-style-type: none"> • Factor XA and Thrombin Inhibitors - Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:35 a.m.	Antidiabetics <ul style="list-style-type: none"> • SGLT2 Inhibitors • Amylin Analogs • DPP4 Inhibitor / SGLT2 Inhibitor Combinations • DPP4 Inhibitor / TZD Combinations • DPP4 Inhibitors • GLP1 Agonist / Insulin Combinations 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> • GLP1 Agonists • Insulin - Intermediate Acting • Insulin - Long Acting • Insulin - Pre-Mixed • Insulin - Rapid Acting • Insulin - Short Acting <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
12:10 p.m.	Lunch (30 min)	All
12:40 p.m.	Antiparkinson Agents <ul style="list-style-type: none"> • Adenosine Receptor Antagonists • Dopaminergics • Monoamine Oxidase Inhibitors (MAOI) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
12:55 p.m.	Sleep Disorder Agents <ul style="list-style-type: none"> • Selective Melatonin Receptor Agonists • Tricyclic Agents • Non-Benzodiazepine <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:05 p.m.	Neuromuscular Agents <ul style="list-style-type: none"> • Spinal Muscular Atrophy - Gene Therapy Agents • Spinal Muscular Atrophy Agents - Antisense Oligonucleotides <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:25 p.m.	Bone Density Regulators <ul style="list-style-type: none"> • Sclerostin Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:30 p.m.	Antidepressants <ul style="list-style-type: none"> • GABA Receptor Modulator - Neuroactive Steroid <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:40 p.m.	Asthma and COPD Agents <ul style="list-style-type: none"> • Leukotriene Modifiers <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:45 p.m.	Drug Utilization Review Board Adjourns	Alex Park, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

